|
|
| Your Biosimilar, Your Journey | Infographic | Cytiva | With many blockbuster drug patents set to expire by 2030, the market is ripe for biosimilar developers to stake their claim. To succeed, they must be strategic and compliant. |
|
|
|
|
By Tamika Drummond, Ph.D., 3Kinnect Solutions Inc. | Biotechs often default to one of two flawed instincts: pursue the biggest name in the space or go with the lowest bidder. To avoid misalignment, look at these less visible factors. | |
|
|
|
By Steve Gens, Gens & Associates Inc. | Most organizations have modernized their global regulatory information management (RIM) systems and improved data quality. Yet modernization and readiness are not the same thing. | |
|
|
|
By Ciera Clayton, BioPhorum | Manufacturing execution system (MES) technical maturity is rising, but adoption across manufacturing sites is uneven. Organizational readiness may hold the key. | |
|
|
|
|
